Over seventy years ago, Nygaard and Brown \[[@CR1]\] used the term thrombophilia to describe patients with an unexplained tendency for, mainly arterial, thrombotic events. Egeberg \[[@CR2]\] used the term in 1965, when he described a Norwegian family that had a remarkable tendency to venous thromboembolism (VTE), and discovered that this was based on an inherited deficiency of antithrombin. In the 80s of the last century, inherited deficiencies of protein C and protein S were described \[[@CR3], [@CR4]\]. Since then various laboratory abnormalities, both hereditary and acquired, have been discovered that increase the risk of VTE. The most prevalent and relatively strong genetic risk factors are gain-of-function mutations, i.e. factor V Leiden that causes resistance to protein C (activated protein C, APC resistance) \[[@CR5]--[@CR7]\], and the prothrombin 20210A mutation that leads to higher levels of prothrombin \[[@CR8]\]. Nowadays, inherited thrombophilia can be identified in about half of all patients presenting with VTE, and appears to provide at least a partial explanation for a previously poorly explained disease \[[@CR9]\]. Over the past decades, testing has increased tremendously for various indications \[[@CR10]\], but whether the results of such tests help in the clinical management of patients has not been settled \[[@CR11], [@CR12]\]. Here, I present an evidence-based approach for the most commonly tested inherited thrombophilias, i.e., deficiencies of antithrombin, protein C, or protein S, and the factor V Leiden and prothrombin G20210A mutations. In such an approach, more important than the strengths of their associations with VTE and its inherent absolute risks, is how testing for thrombophilia is able to reduce these risks.

Mechanisms of thrombophilia {#Sec1}
===========================

The currently established inherited thrombophilias impact either the procoagulant or anticoagulant pathways. A simplified scheme of coagulation and fibrinolysis is depicted in the Fig. [1](#Fig1){ref-type="fig"}. Antithrombin, protein C and protein S are key players in the regulation of coagulation, hence they are referred to as natural anticoagulants. Antithrombin downregulates thrombin, and activated protein C, together with its cofactor protein S, inactivates factors Va and VIIIa. Factor V Leiden refers to a point mutation in the gene at position 1691, leading to a replacement of arginine (Arg) by glutamine (Gln) at amino acid position 506 of the factor Va protein, making it less susceptible for cleavage by activated protein C at this important site. The prothrombin 20210A mutation leads to a normal protein, but at higher levels.Fig. 1Blood Coagulation and Fibrinolysis Simplified scheme of coagulation and fibrinolysis. Coagulation is initiated by a tissue factor (*TF*)---factor VIIa complex that can activate factor IX or factor X, leading to formation of the key enzyme thrombin (*factor IIa*). Tissue factor--dependent coagulation is rapidly inhibited by tissue factor--pathway inhibitor (*TFPI*). Coagulation is maintained through the activation by thrombin of factor XI. Through the intrinsic tenase complex (*factors IXa* and *VIIIa*) and the prothrombinase complex (*factors Xa* and *Va*), the additional thrombin required to down-regulate fibrinolysis is generated by the activation of thrombin-activatable fibrinolysis inhibitor (*TAFI*). The coagulation system is regulated by the protein C pathway. Thrombin activates protein C in the presence of thrombomodulin. Together with protein S (*PS*), activated protein C (*APC*) is capable of inactivating factors Va and VIIIa, which results in a down-regulation of thrombin generation and consequently in an up-regulation of the fibrinolytic system. The activity of thrombin is controlled by the inhibitor antithrombin (*AT*). The solid arrows indicate activation and the broken arrows inhibition

Thrombophilia testing for patients with venous thromboembolism {#Sec2}
==============================================================

Thrombophilia testing is most often considered in patients with VTE, particularly if they are young, have recurrent episodes, have thrombosis at unusual sites, or have a positive family history for the disease. However, although such a strategy may lead to an increased yield of testing, the main question is whether a positive test result alters management. In general, VTE has a tendency to recur, with a cumulative incidence of a second episode of approximately 30% in 8 years \[[@CR13]\]. Patients with a well recognized and transient clinical risk factor such as surgery, eliciting a first VTE have a very low risk of recurrence \[[@CR13]--[@CR15]\]. However, whether the presence of thrombophilia is able to predict recurrence is much less clear, with conflicting results in various studies that compared the prevalences of thrombophilia in patients with recurrent VTE with those in patients without recurrence \[[@CR12]\]. A randomized controlled trial in which testing for thrombophilia in patients with a first episode of VTE is the intervention, and recurrent VTE is the outcome, would be ideal. Testing should then lead to a predefined strategy to prevent recurrence, with for instance a longer or indefinite duration of anticoagulant therapy. To my knowledge, no such trials have been successfully performed \[[@CR11], [@CR16]\].

Several follow-up studies have assessed the risk of recurrent VTE associated with thrombophilic defects. In a cohort of patients from Cambridge, those with a thrombophilic defect, including antithrombin, protein C, or protein S deficiency (HRs ranging from 1.0 to 2.9 for individual deficiencies, which were almost all combined with other thrombophilic defects), or the factor V Leiden mutation (HR 1.4, 95% CI 0.7--2.8), or the prothrombin 20210A mutation (HR 1.7, 95% CI 0.5--5.6), were not at highly increased risk of developing a recurrent venous thrombotic event \[[@CR14]\]. In the Leiden Thrombophilia (LETS) study, no clearly increased risk of recurrent VTE was found for the prothrombotic mutations: factor V Leiden (HR 1.3, 95% CI 0.8--2.1), or prothrombin 20210A mutation (HR 0.7, 95% CI 0.3--2.0) \[[@CR15]\]. A mildly increased risk of recurrent VTE was found in patients with a deficiency in one of the anticoagulants protein C, protein S, or antithrombin (HR 1.8; 95% CI 0.9--3.7). An Italian cohort study reported a similar risk increase of recurrence associated with deficiencies of the anticoagulants (antithrombin deficiency: HR 1.9, 95% CI 1.0--3.9, protein C or S deficiency: HR 1.4, 95% CI 0.9--2.2) \[[@CR17]\]. In a large pooled study of thrombophilic families, we observed a cumulative incidence of VTE recurrences after 10 years of 55% in relatives with a deficiency of antithrombin, protein C or protein S deficiency, as compared to 25% in those with the factor V Leiden mutation, the prothrombin mutation or high levels of FVIIIa \[[@CR18]\].

In order to investigate whether testing for thrombophilia reduces the risk of recurrent VTE in patients with a first episode of thrombosis, for instance by management alterations (such as prolonged use of anticoagulations, avoidance of or intensified prophylaxis in high risk situations) we selected 197 patients from the MEGA case control study who had had a recurrent event during follow-up \[[@CR19]\]. We compared the proportion of these patients who had been tested with the proportion of 324 patients who did not have a recurrence during follow-up, matched for age, sex, year of event and geographical region. Thrombophilia tests were performed in 35% of cases and in 30% of controls. The OR for recurrence was 1.2 (95% CI 0.9--1.8) for tested versus non-tested patients, indicating that testing does not reduce the risk of recurrent VTE in patients who have experienced a first episode.

In conclusion, observational studies show that patients who have had VTE and have hereditary thrombophilia, are at most at a slightly increased risk for recurrence. Furthermore, in real life, no beneficial effect on the risk of recurrent VTE was observed in patients who had been tested for thrombophilia. In general, after a first episode of venous thrombosis, 3--6 months of anticoagulant therapy is considered to have the optimal balance between the risk of treatment (bleeding) and the benefit (prevention of an extension or recurrence of venous thrombosis) \[[@CR20]\]. In the absence of trials that compared routine and prolonged anticoagulant treatment in patients testing positive for thrombophilia, prolonged anticoagulant therapy cannot be justified as it may cause more harm than benefit.

Testing for thrombophilia to modify the risk of a first deep venous thrombosis {#Sec3}
==============================================================================

The risk of VTE in individuals with thrombophilia is, by definition, increased as compared to the general population. In clinical practice, requests to estimate the risk of a first episode of VTE are most often done by asymptomatic individuals with a family history of VTE, with or without a known specific thrombophilic defect. It is important to realize that having a family history of VTE increases the risk of VTE in a first degree relative by approximately two-fold, regardless of the presence of a known hereditary thrombophilic defect \[[@CR21]\]. Still, a potential advantage of testing patients with VTE for thrombophilia may be the identification of asymptomatic family members of thrombophilic patients in order to take preventive measures if tested positive.The risks of a first episode of VTE have been assessed in several family studies with similar design and are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Estimated incidence of a first episode of venous thrombosis in carriers of various thrombophilic defectsAntithrombin, protein C, or protein S deficiency \[[@CR18], [@CR23], [@CR24], [@CR26], [@CR27]\]Factor V Leiden, heterozygous \[[@CR23], [@CR27]--[@CR29]\]Prothrombin 20210A mutation \[[@CR31], [@CR32]\]Factor V Leiden, homozygous \[[@CR30], [@CR35]--[@CR37]\]Overall (%/year, 95% CI)1.5 (0.7--2.8)0.5 (0.1--1.3)0.4 (0.1--1.1)1.8 (0.1--4.0)^**a**^Surgery, trauma, or immobilization (%/episode, 95% CI)8.1 (4.5--13.2)1.8 (0.7--4.0)1.6 (0.5--3.8)--Pregnancy (%/pregnancy, 95% CI)4.1 (1.7--8.3)2.1 (0.7--4.9)2.3 (0.8--5.3)16.3^b^During pregnancy, %, 95% CI1.2 (0.3--4.2)0.4 (0.1--2.4)0.5 (0.1--2.6)7.0^b^Postpartum period, %, 95% CI3.0 (1.3--6.7)1.7 (0.7--4.3)1.9 (0.7--4.7)9.3^b^Oral contraceptive use (%/year of use, 95% CI)4.3 (1.4--9.7)0.5 (0.1--1.4)0.2 (0.0--0.9)--Data apply to individuals with at least one symptomatic first-degree relative^a^ Based on pooled OR of 18 \[[@CR8]--[@CR40]\] and an incidence of 0.1% in non-carriers^b^ Data from family studies, risk estimates lower in other settings

Although antithrombin deficiency has historically been regarded to be the most severe thrombophilic defect leading to a very high risk of thrombosis, in a large population based case--control study antithrombin deficiency (measured as plasma levels \<80 U/dl on two occasions) was associated with a fivefold (95% CI 0.7--34) increased risk of a first deep venous thrombotic event.([@CR22]) Retrospective and prospective studies in families with at least one proband with VTE and antithrombin deficiency found an incidence of first VTE between 0.4% and 1.7% per year in deficient relatives \[[@CR23]--[@CR27]\]. Also for the other hereditary thrombophilias, the overall absolute risk of VTE in asymptomatic relatives has been assessed in numerous studies and is generally low, even during high risk situations such as pregnancy, the postpartum period, surgery, immobilisation, trauma and during the use of oral contraceptives \[[@CR23], [@CR27]--[@CR37]\] (Table [1](#Tab1){ref-type="table"}). Noteworthy, the risk estimates related to surgery, trauma and immobilisation as shown in this table for a large part reflect the situation before standard prophylaxis was routine patient care.

It is clear that the 2% annual major bleeding risk associated with continuous anticoagulant treatment outweighs the risk of venous thrombosis \[[@CR38], [@CR39]\].

For women at fertile age who wish to use oral contraceptives, or have an increased risk of VTE during and after pregnancy, Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} indicate the effect of either avoidance of these risk factors (for oral contraceptives), or taking preventing measures during and/or after pregnancy. The risk of additional venous thrombotic events induced by the use of oral contraceptive is outlined in Table [2](#Tab2){ref-type="table"}, and can be applied to women who have a positive first degree relative with VTE who has a known thrombophilic defect. The values clearly indicate that women with antithrombin, protein C or protein S deficiency have a high risk of VTE provoked by use of oral contraceptives, and that it may be worthwhile to test women from these families to advise those with a deficiency to avoid use of the contraceptive pill. However, it should be noted that women without a deficiency still have a markedly increased risk of oral contraceptive related VTE compared to the general population (0.7 vs. 0.03% per year of use), probably because of co-segregation of yet unknown thrombophilias. Thus, a negative thrombophilia test may lead to false reassurance. These risk estimates are very different for the more common thrombophilias such as factor V Leiden, with a large number of women needing to avoid use of oral contraceptives to avoid 1 VTE, and a number needed to test of 666. Table [3](#Tab3){ref-type="table"} indicates the number needed to test to install prophylactic measurements around pregnancy, again applicable to women from thrombophilic families. Only for women with antithrombin, protein C or protein S deficiency, or those who are homozygous for factor V Leiden, the risks during pregnancy may outweigh the nuisance of daily subcutaneous low-molecular-weight heparin injections and skin reactions, and the very small risk for severe complications of anticoagulant therapy during pregnancy \[[@CR40]--[@CR42]\]. Whether the 80% of pregnancy-related episodes occurring in the 6--12 weeks postpartum justifies prophylaxis during this period is a matter of the physicians' and patients' preference in which the values from Table [3](#Tab3){ref-type="table"} can be useful. It is noteworthy that in these family studies the risk of pregnancy-related VTE in women who do not have the thrombophilic defect is approximately 0.5%, a value in the same range as in the general population \[[@CR43]\]. Hence, withholding prophylaxis to women from thrombophilic families who do not have the defect is supported by evidence.Table 2Estimated number of asymptomatic thrombophilic women who should avoid using oral contraceptives to prevent one VTE, and estimated number needed to testThrombophiliaRisk on OC per year (%)Risk difference per 100 womenN not taking OC to prevent 1 VTN of female relatives to be testedAntithrombin, protein C, or protein S deficiency Deficient relatives4.3^a^3.62856 Non-deficient relatives0.7^a^   Factor V Leiden or prothrombin mutation Relatives with the mutation0.5^a^0.3333666 Relatives without the mutation0.2^a^   Family history of VTE General population, no family history0.03^b^0.025000None General population, positive family history0.06^b^0.042500None^a^ Based on family studies as outlined in Table [1](#Tab1){ref-type="table"}^b^ Based on a population baseline risk of VTE in young women of 0.01% per year \[[@CR64]\], a relative risk of VTE by use oral contraceptives of three \[[@CR65]\], and a relative risk of two of VTE by having a positive family history \[[@CR21]\]Table 3Estimated number of asymptomatic thrombophilic women who should use LMWH prophylaxis during pregnancy and/or the postpartum period to prevent pregnancy-related VTE, and estimated number needed to testThrombophiliaN of female relatives to be tested to prevent VTE during pregnancy^a^N of female relatives to be tested to prevent VTE postpartum^a^Antithrombin, protein C, or protein S deficiency8333Factor V Leiden or prothrombin mutation, heterozygous25060Factor V Leiden, homozygous1410^a^ Based on family studies as outlined in Table [1](#Tab1){ref-type="table"}These estimates apply to women with a positive family history of VTE and assume a 100% efficacy of prophylaxis with LMWH

In conclusion, only in limited situations thrombophilia testing in asymptomatic relatives may be useful. This seems particularly the case in families with antithrombin, protein C or protein S deficiency, or homozygosity for factor V Leiden, and appears limited to women who intend to become pregnant and perhaps, in individual cases of women who would like to use oral contraceptives. In general, appropriate counselling with knowledge of absolute risks should help in making an informed decision in which patient's preferences can be taken into account.

Thrombophilia testing for other clinical indications {#Sec4}
====================================================

Although numerous studies have investigated the association between thrombophilia and arterial cardiovascular diseases, positive and negative studies are equally available \[[@CR44]\]. There is no evidence that the presence of inherited thrombophilia should lead to different secondary prevention, and testing in this clinical setting is not justified.

Inherited thrombophilia has also been implicated in pregnancy complications, such as recurrent miscarriage and fetal death, analogous to the clinical manifestations that are part of the antiphospholipid syndrome \[[@CR45]\]. The association between hereditary thrombophilia varies depending on type of thrombophilia and timing of pregnancy failure \[[@CR46]\], and there is a modest association also between thrombophilia and other adverse pregnancy outcomes, most notably preeclampsia and intra-uterine growth retardation \[[@CR47]\]. However, whether this association can be considered causal remains controversial, as many other factors play a role in the risk of pregnancy complications \[[@CR48]--[@CR51]\]. Therapeutic options to prevent pregnancy complications in women with thrombophilia comprise aspirin as well as (low-molecular-weight) heparin. For women with recurrent pregnancy loss, there is no evidence supporting treatment \[[@CR50], [@CR52]\]. Observational research is hampered by severe methodological flaws or inconsistent results. Two randomized trials have not used an adequate comparator, i.e. no treatment or placebo \[[@CR53], [@CR54]\]. Two recent randomized controlled trials in women with unexplained recurrent miscarriage, the ALIFE study from The Netherlands and the SPIN study from Scotland, were unable to demonstrate a beneficial effect of anticoagulant therapy, compared to no pharmacological treatment or placebo \[[@CR55], [@CR56]\]. Although the ALIFE study was underpowered for subgroup analyses, an a priori planned analysis in women with inherited thrombophilia showed a relative risk for live birth of 1.31 (95% CI 0.74--2.33) for the combined intervention compared to placebo, and 1.22 (95% CI 0.69--2.16) for aspirin, with corresponding absolute difference in live birth rates of 16.3% (95% CI −18.2 to 50.8) and 11.8% (95%CI −21.1 to 44.6) respectively \[[@CR55]\]. The possibility that one or both of these interventions might be beneficial in such women warrants further study in adequately powered, controlled trials. With the current evidence, using anticoagulant therapy to improve the prognosis of a pregnancy in women with pregnancy complications should be considered experimental.

Drawbacks of thrombophilia testing {#Sec5}
==================================

Disadvantages of testing patients with a venous thrombosis for thrombophilia might be the high costs of testing \[[@CR57]\]. Although some cost-effectiveness studies have been published on the topic of testing for thrombophilia, which concluded that in some scenarios testing could indeed be cost-effective, the number of assumptions from inconsistent observational studies seriously hamper their interpretation \[[@CR58], [@CR59]\]. The psychological impact and consequences of knowing to be a carrier of a (genetic) thrombophilic defect is a potential drawback of testing \[[@CR60]\]. Most studies that focused on impact of testing for thrombophilia showed that patients had experienced low psychological distress following thrombophilia testing \[[@CR61], [@CR62]\]. Nevertheless, a qualitative study described several negative effects of both psychological and social origin \[[@CR63]\]. Finally, difficulties in obtaining life or disability insurances are frequently encountered by individuals who are known carriers of thrombophilia, regardless whether they are symptomatic or asymptomatic \[[@CR63]\].

Conclusions {#Sec6}
===========

Despite the increasing knowledge about the etiology of venous thrombosis, testing for hereditary thrombophilia generally does not alter the clinical management of patients with VTE. There are a few exceptions. For some asymptomatic women at fertile age who come from families with a tendency for VTE and a known thrombophilic defect, a positive test may lead to the decision to install prophylaxis during or postpartum in case of pregnancy, or the individual decision to not use oral contraceptives.

In conclusion, because testing for hereditary thrombophilia does not affect clinical management of most patients with VTE, it only serves limited purpose and should not be performed on a routine basis.
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